Search Results - "Hallanger Johnson, Julie"

ACTH ‐secreting pancreatic neuroendocrine neoplasms: A case‐series by Al‐Toubah, Taymeyah, Pelle, Eleonora, Hallanger‐Johnson, Julie, Haider, Mintallah, Strosberg, Jonathan

“…Ectopic Cushing's syndrome (CS) occurs rarely in patients with pancreatic neuroendocrine neoplasms. Early recognition of symptoms is critical given the high…”
Get full text

Adrenal biopsy, as a diagnostic method, is associated with decreased overall survival in patients with T1/T2 adrenocortical carcinoma: A propensity score‐matched analysis by Naffouje, Samer A., Sabesan, Arvind, Hallanger‐Johnson, Julie, Kirtane, Kedar, Gonzalez, Ricardo J., Mullinax, John

“…Introduction The standard diagnosis for adrenocortical carcinoma (ACC) is clinical diagnosis (CD) based on radiographic and biochemical studies. Biopsy…”
Get full text

Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodules by Valderrabano, Pablo, Khazai, Laila, Thompson, Zachary J., Leon, Marino E., Otto, Kristen J., Hallanger‐Johnson, Julie E., Wadsworth, J. Trad, Chung, Christine H., Centeno, Barbara A., McIver, Bryan

“…Background The impact of oncogene panel results on the surgical management of indeterminate thyroid nodules (ITNs) is currently unknown. Methods Surgical…”
Get full text

RET splice site variants in medullary thyroid carcinoma by Saeed-Vafa, Daryoush, Chatzopoulos, Kyriakos, Hernandez-Prera, Juan, Cano, Pedro, Saller, James J, Hallanger Johnson, Julie E, McIver, Bryan, Boyle, Theresa A

“…Medullary thyroid carcinoma (MTC) is an aggressive cancer that is often caused by driver mutations in . Splice site variants (SSV) reflect changes in mRNA…”
Get full text

High Pretreatment DHEA Is Associated with Inferior Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer by Zhang, Yumeng, Darville, Lancia, Hogue, Stephanie, Hallanger Johnson, Julie E, Rose, Trevor, Kim, Youngchul, Bailey, Alexis, Gray, Jhanelle E, Robinson, Lary A

“…Sex difference in the immune response may influence patients' response to immune checkpoint inhibitors (ICIs). We conducted a prospective observation study to…”
Get full text

A Point-of-Care Resource to Improve Care of Patients with Adrenal Mass: www.AdrenalMass.org by Strother, Marshall, Hallanger Johnson, Julie, Kutikov, Alexander

Get full text

Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology by Valderrabano, Pablo, Khazai, Laila, Leon, Marino E, Thompson, Zachary J, Ma, Zhenjun, Chung, Christine H, Hallanger-Johnson, Julie E, Otto, Kristen J, Rogers, Kara D, Centeno, Barbara A, McIver, Bryan

“…ThyroSeq v2 claims high positive (PPV) and negative (NPV) predictive values in a wide range of pretest risks of malignancy in indeterminate thyroid nodules…”
Get full text

Letter to the Editor From Hallanger Johnson and El-Haddad: “Yttrium-90 Selective Internal Radiation Therapy Plus Cryoablation for Recurrent Adrenocortical Carcinoma With Liver Metastases” by Hallanger Johnson, Julie, El-Haddad, Ghassan

Get full text

Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade by Al-Toubah, Taymeyah, Strosberg, Jonathan, Hallanger-Johnson, Julie, El-Haddad, Ghassan

“…Targeted radionuclide therapy plays an increasingly important role in managing endocrine-related tumors and significantly advances the therapeutic landscape…”
Get full text

Cancer Risk Associated with Nuclear Atypia in Cytologically Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis by Valderrabano, Pablo, Khazai, Laila, Thompson, Zachary J, Sharpe, Susan C, Tarasova, Valentina D, Otto, Kristen J, Hallanger-Johnson, Julie E, Wadsworth, J Trad, Wenig, Bruce M, Chung, Christine H, Centeno, Barbara A, McIver, Bryan

“…Indeterminate categories of thyroid cytopathology (categories B-III and B-IV of the Bethesda system) are integrated by a heterogeneous spectrum of cytological…”
Get more information

Cancer Risk Stratification of Indeterminate Thyroid Nodules: A Cytological Approach by Valderrabano, Pablo, Khazai, Laila, Thompson, Zachary J, Leon, Marino E, Otto, Kristen J, Hallanger-Johnson, Julie E, Wadsworth, J Trad, Wenig, Bruce M, Chung, Christine H, Centeno, Barbara A, McIver, Bryan

“…Management recommendations for thyroid nodules rely primarily on the cytological diagnosis. However, 25% of biopsies render an indeterminate cytology for which…”
Get more information

Health Care Providers' and Professionals' Experiences With Telehealth Oncology Implementation During the COVID-19 Pandemic: A Qualitative Study by Turner, Kea, Bobonis Babilonia, Margarita, Naso, Cristina, Nguyen, Oliver, Gonzalez, Brian D, Oswald, Laura B, Robinson, Edmondo, Elston Lafata, Jennifer, Ferguson, Robert J, Alishahi Tabriz, Amir, Patel, Krupal B, Hallanger-Johnson, Julie, Aldawoodi, Nasrin, Hong, Young-Rock, Jim, Heather S L, Spiess, Philippe E

“…Rapid implementation of telehealth for cancer care during COVID-19 required innovative and adaptive solutions among oncology health care providers and…”
Get full text

Yttrium-90 radioembolization of isolated hepatic adrenocortical carcinoma metastases with negative surgical pathology by Lu, Sen, Dhillon, Jasreman, Johnson, Julie Hallanger, El-Haddad, Ghassan

“…Background Adrenocortical carcinoma (ACC) is an uncommon malignancy with an estimated 15,400 new cases annually across the globe. The prognosis is generally…”
Get full text

Fluoride-Related Bone Disease Associated With Habitual Tea Consumption by Johnson, Julie E. Hallanger, MD, Kearns, Ann E., MD, PhD, Doran, Patrick M., MD, Khoo, Teck Kim, MD, Wermers, Robert A., MD

“…Acquired osteosclerosis is a rare disorder of bone formation but an important consideration in adults with sclerotic bones or elevated bone density results. In…”
Get full text

Systemic therapy for adrenocortical carcinoma: a review by Hallanger-Johnson, Julie E.

Get full text

The role of rurality in cancer treatment disruptions among patients with cancer diagnosed with SARS-CoV-2: An analysis of the ASCO Survey on COVID-19 in Oncology Registry by Islam, Jessica Yasmine, Turner, Kea, Hathaway, Cassandra, Hume, Emma, Hallanger-Johnson, Julie E., Tworoger, Shelley, Camacho-Rivera, Marlene

“…6554 Background: U.S. rural cancer patients experience multifactorial barriers to cancer treatment; however, little is known about the impact of the pandemic…”
Get full text

The impact of pre-treatment plasma sex hormones on the immune checkpoint inhibitors response to metastatic non-small cell lung cancer by Zhang, Yumeng, Darville, Lancia, Hogue, Stephanie, Hallanger-Johnson, Julie E., Kim, Youngchul, Gray, Jhanelle Elaine, Robinson, Lary A.

“…e21088 Background: Immune checkpoint inhibitors (ICI) have changed the outcomes in metastatic non-small cell lung cancer (mNSCLC). The immune system partially…”
Get full text

Implementing suicide risk screening as a part of routine cancer care by Donato, Umberto, Nguyen, Oliver, McCormick, Rachael, Hume, Emma, Alishahi, Amir, Islam, Jessica Yasmine, Hallanger-Johnson, Julie E., Gilbert, Scott Michael, Turner, Kea

“…216 Background: Head and neck cancer (HNC) patients are at increased risk for suicide. Few studies have tested approaches to preventing suicide in this…”
Get full text

A review of mitotane in the management of adrenocortical cancer by Del Rivero, Jaydira, Else, Tobias, Hallanger-Johnson, Julie, Kiseljak-Vassiliades, Katja, Raj, Nitya, Reidy-Lagunes, Diane, Srinivas, Sandy, Gilbert, Jill, Vaidya, Anand, Aboujaoude, Emily, Bancos, Irina, Tito Fojo, Antonio

“…Mitotane (Lysodren, o,p'-DDD [1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane)] is currently the only United States Food and Drug Administration and…”
Get full text

Racial/ethnic disparities of cancer treatment disruptions among patients with breast cancer with SARS-CoV-2 infection: An analysis of the ASCO Survey on COVID-19 in Oncology Registry by Islam, Jessica Yasmine, Hathaway, Cassandra, Lee, Kimberley T, Hume, Emma, Turner, Kea, Hallanger-Johnson, Julie E., Tworoger, Shelley, Camacho-Rivera, Marlene

“…6556 Background: The COVID-19 pandemic has led to disruptions in cancer treatment delivery among breast cancer patients in the U.S. However, it is currently…”
Get full text